U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.05
    -0.31 (-0.59%)
     
  • Gold

    1,834.80
    +4.90 (+0.27%)
     
  • Silver

    25.04
    +0.17 (+0.70%)
     
  • EUR/USD

    1.2077
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3541
    -0.0042 (-0.31%)
     
  • USD/JPY

    103.7480
    -0.0520 (-0.05%)
     
  • BTC-USD

    36,264.20
    +205.32 (+0.57%)
     
  • CMC Crypto 200

    703.29
    -31.85 (-4.33%)
     
  • FTSE 100

    6,728.44
    -7.27 (-0.11%)
     
  • Nikkei 225

    28,242.21
    -276.97 (-0.97%)
     

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

·1 min read

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.

A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. A replay of the webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005809/en/

Contacts

Olivia Bloom
Chief Financial Officer
investor@geron.com
media@geron.com